Mortality Reduction by Implantable Cardioverter-Defibrillators in High-Risk Patients With Heart Failure, Ischemic Heart Disease, and New-Onset Ventricular Arrhythmia
An Effectiveness Study
Paul S. Chan, MD*,* and
Rodney A. Hayward, MD ,
* Division of Cardiology, University of Michigan School of Medicine
VA Center for Practice Management and Outcomes Research, VA Ann Arbor Healthcare System
Departments of Internal Medicine and Health Management and Policy, University of Michigan Schools of Medicine and Public Health, Ann Arbor, Michigan.
View larger version (11K):
[in a new window]
|
Figure 1 Unadjusted cardiovascular and noncardiovascular rates of mortality (in %) by treatment group. CV = cardiovascular mortality; ICD = implantable cardioverter-defibrillator.
|
|
View larger version (34K):
[in a new window]
|
Figure 2 Covariate distribution by propensity score quintile. Patients in the lowest propensity score quintile (Q1) are more likely to be older (mean ages for Q1, Q3, and Q5 of 72, 68, and 64, respectively) and have chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), stroke, renal failure (Renal), morbid obesity, peripheral vascular disease (PVD), and an index arrhythmia of cardiac arrest (Arrest). CABG = coronary artery bypass grafting; HTN = hypertension; lipid = hyperlipidemia; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; V. Fib = ventricular fibrillation; V. Tach = ventricular tachycardia; Q1 = quintile 1; Q3 = quintile 3; and Q5 = quintile 5 for propensity scores.
|
|
|
